Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

  • Quintela Fandino, Miguel Angel
  • Apala, Juan V
  • Malon, Diego
  • Mouron, Silvana Andrea
  • Hornedo, Javier
  • Gonzalez-Cortijo, Lucia
  • Colomer, Ramon
  • Guerra, Juan
BACKGROUND: The combined use of a FGFR1 blocker and aromatase inhibitors is appealing for treating breast cancer patients with FGFR1 amplification. However, no pharmacodynamic studies have addressed the effects of this combined target modulation. We conducted a phase 0/I clinical trial in an adjuvant setting, with the goal of obtaining pharmacodynamic proof of the effects of combined aromatase and FGFR1 inhibition and to establish the RP2D for nintedanib combined with letrozole. PATIENTS AND METHODS: Women with early-stage luminal breast cancer were eligible for enrollment in the study. Dose level 1 was nintedanib (150 mg/bid) plus letrozole (2.5 mg/day) administered for a single 28-day cycle (DLT assessment period), followed by a classic 3 + 3 schedule. FGF23 and 17-B-estradiol levels were determined on days 0 and 15; pharmacokinetic parameters were assessed on days 1 and 28. Patients were allowed to continue treatment for 6 cycles. The primary study endpoint was a demonstration of FGFR1 modulation (defined as a 25% increase in the plasma FGF23 level). RESULTS: A total of 19 patients were enrolled in the study (10 in the expansion cohort following dose escalation). At the RP2D (nintedanib 200 mg/bid plus letrozole 2.5 mg/day), we observed a 55% mean increase in the plasma FGF23 level, and 81.2% of the patients had no detectable level of 17-B-estradiol in their plasma (87.5% of the patients treated with letrozole alone). Nintedanib and letrozole displayed a pharmacokinetic interaction that led to three- and twofold increases in their respective plasma concentrations. Most G3 toxic events (5 out of 6: 2 diarrhea and 3 hypertransaminasemia) occurred subsequent to the DLT assessment period. CONCLUSION: Combined treatment with nintedanib (200 mg/bid) plus letrozole (2.5 mg/day) effectively suppressed FGFR1 and aromatase activity, and these respective doses can be used as starting doses in any subsequent trials. However, drug-drug interactions may produce tolerability issues when these drugs are co-administered for an extended time period (e.g., 6 months). Patients enrolled in future trials with these drugs should be carefully monitored for their FGF23 levels and signs of toxicity, and those findings should guide individualized treatment decisions. TRIAL REGISTRATION: This trial was registered at www.clinicaltrials.gov under reg. # NCT02619162, on December 2, 2015.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Safety and performance of a hybrid closed-loop insulin delivery system with carbohydrate suggestion in adults with type 1 diabetes prone to hypoglycemia

  • Mesa, Álex
  • Beneyto, Aleix
  • Viaplana, Judith
  • Vehí, Josep
  • Conget, Ignacio
  • Giménez, Marga
  • Martín-SanJosé, Juan-Fernando|||0000-0002-3247-6156
  • Bondía Company, Jorge|||0000-0001-7286-3719
[EN] Aims: To evaluate the safety and performance of a hybrid closed-loop (HCL) system with automatic carbohydrate suggestion in adults with type 1 diabetes (T1D) prone to hypoglycemia.Methods: A 32-hour in-hospital pilot study, including a night period, 4 meals and 2 vigorous unannounced 45minute aerobic sessions, was conducted in 11 adults with T1D prone to hypoglycemia. The primary outcome was the percentage of time in range 70-180 mg/dL (TIR). Main secondary outcomes were time below range < 70 mg/dL (TBR < 70) and < 54 (TBR < 54). Data are presented as median (10th-90th percentile ranges).Results: The participants, 6 (54.5%) men, were 24 (22-48) years old, and had 22 (9-32) years of T1D duration. All of them regularly used an insulin pump and a continuous glucose monitoring system. The median TIR was 78.7% (75.6-91.2): 92.7% (68.2-100.0) during exercise and recovery period, 79.3% (34.9-100.0) during postprandial period, and 95.4% (66.4-100.0) during overnight period. The TBR < 70 and TBR < 54 were 0.0% (0.0-6.6) and 0.0% (0.0-1.2), respectively. A total of 4 (3-9) 15-g carbohydrate suggestions were administered per person. No severe acute complications occurred during the study.Conclusions: The HCL system with automatic carbohydrate suggestion performed well and was safe in this population during challenging conditions in a hospital setting., This work has been funded by Instituto de Salud Carlos III (ISCIII) through the project "PI19/01865" and co-funded by the European Union. It was also partially supported by the Spanish Ministry of Science and Innovation through grants PID2019-107722RB-C21 and PID2019-107722RB-C22, and in part by the Spanish Ministry of Universities and by the European Union through Next GenerationEU (Margarita Salas). Finally, it was also partially funded by Hospital Clinic de Barcelona under "Contractes Clinic de Recerca Emili Letang-Josep Font" 2021.The authors thank the research participants for their time, insight and dedication; as well as the staff at Hostal Lleida and at the Diabetes unit and hospital food service at Hospital Clinic de Barcelona for invaluable help.
RUA. Repositorio Institucional de la Universidad de Alicante
Publication Otros (Other)

La helenización y feminización del concepto de pax asociado a Jano. Cambios en el lenguaje de paz en la Antigua Roma (s. III a. C.-s. I d. C.), The hellenisation and feminisation of the of the pax concept associated with Janus. Changes in the language of peace in Ancient Rome (3rd century BC-1st century AD)

  • Ruiz Vivas, Carmen María
El presente trabajo es un análisis desde una perspectiva de género de la evolución del concepto de pax asociado al dios Jano en la Roma antigua. Se pone el foco en aquellos elementos asociados a lo masculino y femenino en el lenguaje de pax romano, y en su evolución y resignificación. Durante la época romana las puertas de Jano simbolizaron las relaciones externas de la ciudad de Roma, abriéndose cuando había guerra y cerrándose cuando había paz externa. Este ritual del cierre de las puertas se revitalizó durante el principado de Augusto, lo que se plasmó en la literatura e iconografía augustea, asociándolo además a la idea de pax y saeculum aureum. El concepto de pax hasta entonces había aludido a la sumisión del otro a lo largo de la República; fue durante la crisis de la misma cuando se usó como promesa política que implícitamente significaba el final de los enfrentamientos, externos e internos, y el bienestar subyacente. El auge de la pax se produjo durante el Principado de Augusto, quien se presentó como garante de ese principio. En este contexto la pax adquirió nuevas connotaciones, asimilándose a Eirene, diosa de la paz en el mundo griego. Por tanto, el concepto de pax asociado a Jano, deidad que había simbolizado la guerra y la paz externa en época republicana, se helenizó y feminizó al representarse incluso en forma de mujer. Este trabajo pretende contribuir a la comprensión de cómo los conceptos de paz fueron reformulados y redefinidos durante la crisis de la República y empleados como parte de la propaganda de la Pax Augusta. Para ello se han analizado tanto fuentes numismáticas e iconográficas como textos escritos.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

  • Quintela-Fandino, Miguel
  • Holgado, Esther
  • Manso, Luis
  • Cortés Castan, Javier
  • Morales, Serafin
  • Bermejo, Begoña
  • Colomer, Ramon
Bevacizumab; Durvalumab; Càncer de mama HER2 negatiu, Bevacizumab; Durvalumab; Cáncer de mama HER2 negativo, Bevacizumab; Durvalumab; HER2-negative breast cancer, Background Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer. Methods Patients had advanced HER2-negative disease that progressed while receiving single-agent bevacizumab maintenance as a part of a previous chemotherapy plus bevacizumab regimen. Treatment consisted of bi-weekly durvalumab plus bevacizumab (10 mg/kg each i.v.). Peripheral-blood mononuclear cells (PBMCs) were obtained before the first durvalumab dose and every 4 weeks and immunophenotyped by flow-cytometry. A fresh pre-durvalumab tumor biopsy was obtained; gene-expression studies and immunohistochemical staining to assess vascular normalization and characterize the immune infiltrate were conducted. Patients were classified as “non-progressors” if they had clinical benefit (SD/PR/CR) at 4 months. The co-primary endpoints were the changes in the percentage T cell subpopulations in PBMCs in progressors versus non-progressors, and PFS/OS time. Results Twenty-six patients were accrued. Median PFS and OS were 3.5 and 11 months; a trend for a longer OS was detected for the hormone-positive subset (19.8 versus 7.4 months in triple-negatives; P = 0.11). Clinical benefit rate at 2 and 4 months was 60% and 44%, respectively, without significant differences between hormone-positive and triple-negative (P = 0.73). Non-progressors’ tumors displayed vascular normalization features as a result of previous bevacizumab, compared with generally abnormal patterns observed in progressors. Non-progressors also showed increased T-effector and T-memory signatures and decreased TREG signatures in gene expression studies in baseline—post-bevacizumab—tumors compared with progressors. Notably, analysis of PBMC populations before durvalumab treatment was concordant with the findings in tumor samples and showed a decreased percentage of circulating TREGs in non-progressors. Conclusions This study reporting on sequential bevacizumab+durvalumab in breast cancer showed encouraging activity in a heavily pre-treated cohort. The correlative studies agree with the preclinical rationale supporting an immunopriming effect exerted by antiangiogenic treatment, probably by reducing TREGs cells both systemically and in tumor tissue. The magnitude of this benefit should be addressed in a randomized setting., MQF is a recipient of the following grants: AES - PI16/00354 funded by the ISCIII and co-funded by the European Regional Development Fund (ERDF) and B2017/BMD3733 (Immunothercan-CM) - Call for Coordinated Research Groups from Madrid Region - Madrid Regional Government - ERDF funds. SM is a recipient of the following grants: Spanish Ministerio de Economía y Competitividad (MINECO) (SAF2017-83732-R; AEI/FEDER, EU) and co-funded by Comunidad de Madrid (B2017/BMD3733; Immunothercan-CM). RC is a recipient RC is a recipient of the ISCIII grants PIE15/00068 and PI17/01865. The study was also funded by CRIS Contra el Cancer Foundation and Astra Zeneca Spain. Astra Zeneca Spain provided durvalumab.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer, a pilot clinical trial

  • Quintela-Fandino, Miguel|||0000-0003-1648-1964
  • Holgado, Esther
  • Manso, Luis|||0000-0002-1683-550X
  • Morales, Serafin|||0000-0001-7445-4193
  • Bermejo, Begoña
  • Colomer, Ramon|||0000-0002-6393-3444
  • Apala, Juan V.
  • Blanco, Raquel
  • Muñoz, Manuel
  • Caleiras, Eduardo
  • Iranzo, Vega
  • Martínez López, Mario
  • Dominguez, Orlando
  • Hornedo, Javier
  • Gonzalez-Cortijo, Lucia
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Gasol Cudos, Ariadna
  • Malon, Diego
  • Lopez-Alonso, Antonio
  • Moreno-Ortíz, María C.
  • Mouron, Silvana
  • Mañes, Santos
Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer. Patients had advanced HER2-negative disease that progressed while receiving single-agent bevacizumab maintenance as a part of a previous chemotherapy plus bevacizumab regimen. Treatment consisted of bi-weekly durvalumab plus bevacizumab (10 mg/kg each i.v.). Peripheral-blood mononuclear cells (PBMCs) were obtained before the first durvalumab dose and every 4 weeks and immunophenotyped by flow-cytometry. A fresh pre-durvalumab tumor biopsy was obtained; gene-expression studies and immunohistochemical staining to assess vascular normalization and characterize the immune infiltrate were conducted. Patients were classified as "non-progressors" if they had clinical benefit (SD/PR/CR) at 4 months. The co-primary endpoints were the changes in the percentage T cell subpopulations in PBMCs in progressors versus non-progressors, and PFS/OS time. Twenty-six patients were accrued. Median PFS and OS were 3.5 and 11 months; a trend for a longer OS was detected for the hormone-positive subset (19.8 versus 7.4 months in triple-negatives; P = 0.11). Clinical benefit rate at 2 and 4 months was 60% and 44%, respectively, without significant differences between hormone-positive and triple-negative (P = 0.73). Non-progressors' tumors displayed vascular normalization features as a result of previous bevacizumab, compared with generally abnormal patterns observed in progressors. Non-progressors also showed increased T-effector and T-memory signatures and decreased T signatures in gene expression studies in baseline-post-bevacizumab-tumors compared with progressors. Notably, analysis of PBMC populations before durvalumab treatment was concordant with the findings in tumor samples and showed a decreased percentage of circulating T in non-progressors. This study reporting on sequential bevacizumab+durvalumab in breast cancer showed encouraging activity in a heavily pre-treated cohort. The correlative studies agree with the preclinical rationale supporting an immunopriming effect exerted by antiangiogenic treatment, probably by reducing T cells both systemically and in tumor tissue. The magnitude of this benefit should be addressed in a randomized setting. (www.clinicaltrials.gov):. Registered on June 16, 2020.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

  • Quintela-Fandino, Miguel
  • Holgado, Esther
  • Manso, Luis
  • Cortés Castan, Javier
  • Morales, Serafin
  • Bermejo, Begoña
  • Colomer, Ramon
Bevacizumab; Durvalumab; Càncer de mama HER2 negatiu, Bevacizumab; Durvalumab; Cáncer de mama HER2 negativo, Bevacizumab; Durvalumab; HER2-negative breast cancer, Background Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer. Methods Patients had advanced HER2-negative disease that progressed while receiving single-agent bevacizumab maintenance as a part of a previous chemotherapy plus bevacizumab regimen. Treatment consisted of bi-weekly durvalumab plus bevacizumab (10 mg/kg each i.v.). Peripheral-blood mononuclear cells (PBMCs) were obtained before the first durvalumab dose and every 4 weeks and immunophenotyped by flow-cytometry. A fresh pre-durvalumab tumor biopsy was obtained; gene-expression studies and immunohistochemical staining to assess vascular normalization and characterize the immune infiltrate were conducted. Patients were classified as “non-progressors” if they had clinical benefit (SD/PR/CR) at 4 months. The co-primary endpoints were the changes in the percentage T cell subpopulations in PBMCs in progressors versus non-progressors, and PFS/OS time. Results Twenty-six patients were accrued. Median PFS and OS were 3.5 and 11 months; a trend for a longer OS was detected for the hormone-positive subset (19.8 versus 7.4 months in triple-negatives; P = 0.11). Clinical benefit rate at 2 and 4 months was 60% and 44%, respectively, without significant differences between hormone-positive and triple-negative (P = 0.73). Non-progressors’ tumors displayed vascular normalization features as a result of previous bevacizumab, compared with generally abnormal patterns observed in progressors. Non-progressors also showed increased T-effector and T-memory signatures and decreased TREG signatures in gene expression studies in baseline—post-bevacizumab—tumors compared with progressors. Notably, analysis of PBMC populations before durvalumab treatment was concordant with the findings in tumor samples and showed a decreased percentage of circulating TREGs in non-progressors. Conclusions This study reporting on sequential bevacizumab+durvalumab in breast cancer showed encouraging activity in a heavily pre-treated cohort. The correlative studies agree with the preclinical rationale supporting an immunopriming effect exerted by antiangiogenic treatment, probably by reducing TREGs cells both systemically and in tumor tissue. The magnitude of this benefit should be addressed in a randomized setting., MQF is a recipient of the following grants: AES - PI16/00354 funded by the ISCIII and co-funded by the European Regional Development Fund (ERDF) and B2017/BMD3733 (Immunothercan-CM) - Call for Coordinated Research Groups from Madrid Region - Madrid Regional Government - ERDF funds. SM is a recipient of the following grants: Spanish Ministerio de Economía y Competitividad (MINECO) (SAF2017-83732-R; AEI/FEDER, EU) and co-funded by Comunidad de Madrid (B2017/BMD3733; Immunothercan-CM). RC is a recipient RC is a recipient of the ISCIII grants PIE15/00068 and PI17/01865. The study was also funded by CRIS Contra el Cancer Foundation and Astra Zeneca Spain. Astra Zeneca Spain provided durvalumab.